Drugs / 2-Deoxy-D-Glucose
2-Deoxy-D-Glucose
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00096707 | Feb 2004 → Jul 2008 | breast cancer, gastric cancer, head and neck cancer, lung cancer +1 | Threshold Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05605301 | Sep 2022 → Feb 2024 | epilepsy | University of Virginia | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06375772 Comparator | Apr → Aug 2024 | nasopharyngitis | G.ST Antivirals GmbH | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2020-07-29 | Moleculin Biotech, Inc. | Results Additional Independent Research Further Supports Glucose Metabolism as Important COVID-19 Target moleculin.com ↗ |
| 2020-04-13 | CNS Pharmaceuticals, Inc. | Results CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals cnspharma.com ↗ |
| 2020-04-08 | Moleculin Biotech, Inc. | Results Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100% moleculin.com ↗ |
| 2018-11-08 | Moleculin Biotech, Inc. | Results Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122 moleculin.com ↗
A study recently published in the American Cancer Journal of Cancer Research (Am J Cancer Res 2018;8(9):1837-1846) involving researchers at MD Anderson and the Peking University Cancer Hospital & Institute has found that 2-deoxyglucose (2-DG) has the potential to decrease resistance to immune checkpoint blockade therapy in triple-negative breast cancer (TNBC) in a process known as “glycosylation.” |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-07-29 | Moleculin Biotech, Inc. | Additional Independent Research Further Supports Glucose Metabolism as Important COVID-19 Target moleculin.com ↗ |
| 2020-04-13 | CNS Pharmaceuticals, Inc. | CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals cnspharma.com ↗ |
| 2020-04-08 | Moleculin Biotech, Inc. | Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100% moleculin.com ↗ |
| 2018-11-08 | Moleculin Biotech, Inc. | Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122 moleculin.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-Deoxy-D-Glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605301 ↗ |
| Known as | 2-deoxy-d-mannose | ChEMBL registry synonym — accepted as the source's own label CHEMBL1880349 ↗ |
| Known as | 2DG | “2-deoxy-D-glucose (2DG) is a synthetic glucose analog under development by Threshold Pharmaceuticals, Inc. that exploits the differences in metabolism between normal and...” NCT00096707 ↗1“Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy” NCT05605301 ↗ |
| Known as | BA 2758 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1880349 ↗ |
| Known as | D-arabino-2-desoxyhexose | ChEMBL registry synonym — accepted as the source's own label CHEMBL1880349 ↗ |
| Known as | NSC-15193 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1880349 ↗ |
| Action | Inhibit | “the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel” PMID 23228990 ↗ Dec 2012 |
| Modality | Small molecule | “2-deoxy-D-glucose (2DG) is a synthetic glucose analog under development by Threshold Pharmaceuticals, Inc.” NCT00096707 ↗ |
| Route | Oral | “2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg” PMID 23228990 ↗ Dec 2012 |